Pathologic Complete Response and Toxicity Results from the STAR-01 Trial Evaluating the Addition of Oxaliplatin to Neodjuvant Chemoradiation for Locally Advanced Rectal Cancer
b'The addition of oxaliplatin to fluorouracil-based neoadjvuant chemoradiation for locally advanced rectal cancer significantly increases toxicity but does not improve the pathologic complete response rate.'